Abstract

Covid- 19 contamination normally starts within the breathing tract in which it could reason bilateral pneumonia. The disorder can evolve into acute respiratory syndrome and multi-organ failure; because of viral expand within the blood and an immoderate inflammatory response together with cytokine storm. Antiviral and anti-cytokine tablets have validated to be poorly or in-powerful in preventing disorder progression, and mortality. Persistent efficacy of antiviral tablets might be because of overdue administration, whilst the virus has brought about the inflammatory response and is now not the primary protagonist. We propose in this review article that Methylene Blue could be a therapy option for Corona Virus Disease in 2019 especially in patients with mild or moderate symptom. We found that methylene blue; a tricyclic phenothiazine compound permitted through the FDA for the remedy of methemoglobinemia and used for different clinical applications inhibits this interaction. It inhibited the access of a SARS-CoV-2 spike bearing pseudovirus into ACE2-expressing cells with comparable IC50 value. Hence, its antiviral activity in opposition to SARS-CoV-2 may want to make a contribution in making less expensive and broadly to be had drug doubtlessly beneficial within the prevention and remedy of COVID-19 as an oral or inhaled medication.